| Name | Title | Contact Details |
|---|
The BIG3 is the premier league for 3v3 hoops. Featuring many of the worlds most popular and accomplished athletes.
The CEDES Group offers its innovative solutions for elevators, escalators, industrial doors, and warehouse management systems in more than 60 countries. We develop intelligent and safe sensing, control and communication devices that provide actionable data streams for higher operational and maintenance efficiency. Our product portfolio ranges from simple photoelectric sensors, through highly complex 3D camera systems in cutting-edge ToF (Time-of-Flight) technology, to complete safety-related control systems and smart IoT-enabling devices.
Yokogawa Electric Corporation is a global leader in measurement, control, and information technologies. Founded in 1915 in Tokyo, Japan, the company began as a small laboratory focused on producing instruments that were primarily imported at the time. Today, Yokogawa operates in 60 countries and employs over 17,365 people, with a significant presence in North America. The company offers a diverse range of products and services, including measurement instruments, advanced control solutions for industrial automation, and information technologies for data management and analysis. Yokogawa serves various industries such as energy, chemicals, pharmaceuticals, and food, helping clients tackle complex production and operations management challenges. Their commitment to quality, innovation, and societal contribution guides their operations and partnerships with customers.
Were developing tech to feed the world. The world is running out of phosphorus. Most of the worlds phosphorus is used to grow food to feed to animals to produce meat. Manure isnt returned to growing regions, and instead leads to algal blooms and nutrient pollution. Were fixing this problem with tech to produce fertilizer from manure, helping farmers grow better food at a price farmers can afford.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.